This inventor holds 32 USPTO granted patents and 14 published patent applications, plus 1 CIPO patent and 18 EPO patents, primarily in Cancer Diagnostics. Top assignees: The General Hospital Corporation, Dana-Farber-Cancer Institute Inc., Massachusetts Institute of Technology. Active years: 1994-2025.
Location History:
- Cambridge, MA (US) (1994 - 2001)
- Newton, MA (US) (2017 - 2022)
- Chestnut Hill, MA (US) (2001 - 2024)
- Chesnut Hill, MA (US) (2020 - 2024)
Company Filing History:
26 out of 3,071 
8 out of 1,266 
4 out of 8,578 
Years Active: 1994-2025
Areas of Expertise:
Title: The Innovative Journey of Daniel Arie Haber
Introduction
Daniel Arie Haber, based in Newton, MA, has established himself as a prominent inventor with an impressive portfolio of 30 patents. His work primarily focuses on groundbreaking advancements in cancer treatment and diagnostics, marking significant contributions to the field of medical research.
Latest Patents
Among his most recent innovations are the patents for "Targeting Human Satellite II (HSATII)" and "Digital Analysis of Circulating Tumor Cells in Blood Samples." The HSATII patent details methods for treating various cancer types, particularly those of epithelial origin, utilizing sequence-specific agents like oligonucleotides to target human satellite II effectively. On the other hand, his work on the digital analysis of circulating tumor cells (CTCs) presents novel assay techniques that promise ultra-high sensitivity and specificity for early disease detection and monitoring. This involves microfluidic isolation of CTCs and the digital detection of RNA derived from these cells, paving the way for advanced cancer diagnostics.
Career Highlights
Daniel has honed his expertise while working at notable institutions such as the General Hospital Corporation and the Dana-Farber Cancer Institute Inc. His contributions in these environments have further solidified his reputation as an innovator in cancer research and treatment methodologies.
Collaborations
Throughout his career, Daniel has collaborated with esteemed colleagues like Shyamala Maheswaran and Daphne Winifred Bell. These partnerships have facilitated a rich exchange of ideas and fostered innovative solutions in their shared areas of research.
Conclusion
Daniel Arie Haber's patent portfolio and contributions to cancer research signify a profound impact on medical science. His innovative approaches and collaborative efforts are paving the way for future advancements in the detection and treatment of cancer, positioning him as a key figure in his field.